IL6 and breast carcinoma: MiR-203 directly inhibits the SOCS pathway in MCF7 cells which suppresses breast cancer progression while miR-7 directly binds to 3′-UTR of IL-6 to negatively regulate its expression which results in antitumorigenic and antimetastatic effects in breast cancer.